Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Goodwill & Intangibles (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Goodwill & Intangibles for 11 consecutive years, with $55.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Goodwill & Intangibles changed N/A to $55.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $55.4 million, a N/A change, with the full-year FY2025 number at $55.4 million, up 5.62% from a year prior.
  • Goodwill & Intangibles was $55.4 million for Q3 2025 at Aytu Biopharma, roughly flat from $55.4 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $151.3 million in Q2 2021 to a low of $8.6 million in Q1 2022.
  • A 5-year average of $73.3 million and a median of $70.3 million in 2022 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: skyrocketed 400.42% in 2021, then plummeted 85.7% in 2022.
  • Aytu Biopharma's Goodwill & Intangibles stood at $140.6 million in 2021, then plummeted by 50.84% to $69.1 million in 2022, then fell by 19.39% to $55.7 million in 2023, then grew by 28.28% to $71.5 million in 2024, then decreased by 22.48% to $55.4 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Goodwill & Intangibles are $55.4 million (Q3 2025), $55.4 million (Q2 2025), and $71.5 million (Q1 2025).